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Follow upAbstract Objective: To identify the value of integrated PET/CT in the follow up of chest tumors.
Patients and methods: Whole body PET/CT studies were performed on 29 patients of variable pri-
mary and secondary chest tumors.
Results: Our ﬁndings indicate that FDG PET/CT has an important impact on evaluation and fol-
low up of chest tumors, as it delineated the metabolic activity of the disease in 21 patients (72.41%),
outlined the metabolic activity of the tumoral residue in 4 patients postoperatively (13.79%), delin-
eated the metabolic activity of the disease in 2 patients preparing for BMT (6.89%), it differentiated
between tumoral residue and post irradiation pneumonitis in 1 patient (3.44%), while it was used
for the initial assessment of the metabolic activity of the disease before determining line of treatment
in one patient and subsequent follow up.
Conclusion: Integrated PET/CT imaging, which combines both functional and morphologic imag-
ing in a single examination, has shown how the initial staging and subsequent follow-up of patients
with chest tumors can supersede the traditional methods of evaluation in terms of diagnostic accu-
racy and has an impact on the management. Limitations we encountered were subcentimetric pul-
monary nodules, below 7–8 mm (beyond PET resolution) which can be overcome by short follow
up.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
In oncological imaging, the goals are lesion detection and
localization including anatomical correlation with structuressuch as vessels, lesion characterization, proper staging, and
treatment success. Some of these goals require precise anatom-
ical imaging, whereas others demand molecular techniques (1).
Current imaging studies provide valuable information, still not
speciﬁc enough to aid in clinical management. CT and MRI
rely on anatomic and morphologic changes for diagnosing,
staging and follow-up, however, many lesions remain
indeterminate making the distinction between benign and
malignant disease a constant challenge. Positron emission
Table 2 Patient demographics.
Number
of patients
Age
range
Sex Preliminary
diagnosis
29 14–65 17 male 27 primary chest tumors
7 lung tumors
2 pleural tumors
2 chest wall tumors
6 mediastinal tumors
7 lymphoma
5 secondary chest tumors
12 female
680 H. Nabil et al.tomography (PET) offers a different approach to diagnosis of
chest diseases (2). PET performed with 2-ﬂuoro-2-deoxy-glu-
cose (FDG) has proved valuable in providing important
tumor-related qualitative and quantitative metabolic informa-
tion that is critical to diagnosis and follow-up. It has been
reported to increase diagnostic accuracy in the differentiation
of benign and malignant lesions and to improve identiﬁcation
of nodal metastasis. Functional scans obtained with FDG-
PET not only are complementary to those obtained with con-
ventional modalities, but also may be more sensitive because
alteration in tissue metabolism generally precede anatomic
changes (3). It was thus a challenge to try to identify the value
of integrated PET/CT in the follow up of chest tumors, inves-
tigating a group of 29 patients, who either had indeterminate
CT ﬁndings or needed additional functional imaging through-
out the course of their treatment.2. Patients and methods
This is a cross sectional study which included 29 patients over
a period of 2 years who were known to have primary or sec-
ondary chest tumors by recent CT, referred for follow up after
treatment.
The exclusion criterion was for uncontrolled diabetic
patients.
The study included 29 patients of variable chest malignancies
(17 male patients, 12 female patients; mean age ± standard
deviation SD: 40.19 ± 17.087 years; age range: 14–65 years).
The indications for PET/CT examination were variable; 21
patients (72.41%) were referred for assessment of treatment
response, 4 patients (13.79%) were referred for assessment of
activity of the residual mass post operatively, 2 patients
(6.89%) were referred for assessment before BMT, 1 patient
(3.44%) was referred for differentiation between tumoral resi-
due or irradiation pneumonitis and 1 patient (3.44%) was
referred for assessment before determination of the treatment
line (Tables 1 and 2).
2.1. Patient demographics
The study population was split into two major groups:
Group I: Included 24 patients with primary chest tumors,
further subgrouped into
I-A: lung cancer (n= 7) (24.13%).
I-B: pleural tumors (n= 2) (6.89%).
I-C: chest wall tumors (n= 2) (6.89%).
I-D: mediastinal tumors (n= 6) (20.68%).Table 1 Indications of PET/CT.
Aim of the study Frequency Percent (%)
Assessment before preparation for BMT 2 6.89
Assessment of activity of the residual
mass postoperatively
4 13.79
Assessment of treatment response 21 72.41
Determination of treatment line 1 3.44
Diﬀerentiation between residue and
irradiation pneumonitis
1 3.44
Total 29 100.0I-E: lymphoma (n= 7) (24.13%).
Group II: Included 5 patients with secondary chest tumors.
3 patients had metastatic breast cancer.
1 patient had metastatic papillary thyroid cancer.
1 patient had metastatic colonic adenocarcinoma.
2.2. Patient preparation
Adequate patient preparation rules were strictly followed.
Patients were instructed to fast, except for glucose-free hydra-
tion for 4–6 h before injection of 18F-FDG.
2.3. Scan protocol
The scan was performed 40–60 min after IV injection of
3.7 MBq/kg; maximum dose 370 MBq 0.1 millicurie/kilogram
(mCi/kg); maximum dose = 20 mCi/kg of 18F-FDG. The
patients were examined in supine position. A whole body
examination was performed starting from skull base to mid
thighs. A PET emission scan was performed over several bed
positions (5 to 7), each with an axial ﬁeld of view of approxi-
mately 15 cm per bed position with an in-plane spatial resolu-
tion of 4 mm covering the same ﬁeld of view as with CT. The
acquisition time of emission data was 2 min per bed position in
the two dimensional mode. The total examination time ranged
between 13 and 17 min. A fully diagnostic CT scan was per-
formed using the following parameters: 350 mA, 120 kV,
0.5 s tube rotation time, slice thickness 5 mm, 8-mm table feed
and 3 mm incremental reconstruction. IV contrast administra-
tion (120 mL) of a low-osmolarity iodinated contrast agent
(Ultravist 300, Schering, Berlin, Germany) and negative oral
contrast agent (water) for bowel were used.
2.4. Data interpretation
Images were reconstructed and viewed on workstation (Syngo
Multimodality Workplace, Siemens Medical Solutions), which
provided multi-planar reformatted PET, CT and fused PET/
CT images with linked cursors as well as MIP PET images
in video mode. PET images were reviewed by an experienced
nuclear medicine physician. CT images were analyzed sepa-
rately by two experienced radiologists blinded to each other’s
ﬁndings. Fused PET/CT images were then analyzed separately
by each of the three. In case of CT images, if the recorded ﬁnd-
ings by the two radiologists were not the same, they had to
reach a consensus together. While for fused PET/CT images,
if the interpreted ﬁndings by any of the three readers were
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two of them.
2.5. PET images
Analysis of PET images was via visual and semi quantitative
assessment (SUV max measurement). Positive lesions were
recorded at areas of high FDG uptake. SUV max was mea-
sured at each lesion and compared to background activity.
The standard background activity was measured in the liver
(right lobe) in patients having diseased liver, the background
activity was measured at the mediastinal blood pool.
2.6. CT images
Detected areas of abnormal FDG uptake on PET images were
further analyzed on CT images.
2.7. Fused PET/CT images
On interpreting fused PET/CT images, lesions were considered
positive when areas of intense FDG uptake (>liver or medias-
tinal blood pool). Lesions were considered negative when lack-
ing high FDG uptake (6liver or mediastinal blood pool)
despite suspicious corresponding CT ﬁndings if any.
When areas of intense FDG uptake (>liver or mediastinal
blood pool). Lesions were considered negative when lacking
high FDG uptake (6liver or mediastinal blood pool), despite
suspicious corresponding CT ﬁndings if any.
3. Results
As regards initial CT ﬁndings, all cases (29) showed inconclu-
sive ﬁndings as regards treatment response (21 cases), tumor
residual versus radiation induced pneumonitis (1 case), postop-
erative residual (4 cases) and data were not conclusive before
bone marrow transplant in 2 cases. Assessment of metabolicTable 3 Percentage of not conclusive CT ﬁndings.
Initial CT data
Not conclusive for diﬀerentiation between tumoral residue and irradiatio
Not conclusive for assessment of the metabolic activity of the disease for
Not conclusive for postoperative evaluation
Not conclusive for evaluation of treatment response
Not conclusive for evaluation of the disease for preparing BMT
Total
Table 4 Percentage of various follow up disease processes on PET
PET/CT follow up ﬁndings
Progressive course
Stationary course followed by progressive course
Stationary course
Regressive course
Regressive course followed by progressive course
Marked disease regression then progression then complete remission
Complete remission
Totalactivity was crucial in one case, before establishing further line
of treatment (Table 3).
The initial fused PET/CT images were then analyzed and 28
out of 29 patients were positive for metabolically active FDG
avid tumoral masses, while one patient showed no metabolic
activity. Further follow up studies revealed: 8 patients had dis-
ease progression, 1 patient showed a stationary course fol-
lowed by progression, 4 patients had a stationary course all
through the study, 7 patients showed disease regression, 1
patient had regressive disease, followed by progressive course
and 1 patient had marked disease regression then progression
then complete remission, 7 patients had a negative study (com-
plete remission) (Table 4).
As shown in Table 4 at the end of the study 9 out of 29
patients were cured and 20 patients needed continuation of
treatment (Table 5).
Accordingly, 25 patients received CTH, 14 received RTH
and 12 patients underwent surgery. This indicates that most
patients received mixed lines of treatment.
We reported ﬁndings beyond PET resolution in 2 patients
out of 29 patients, in the form of multiple subcentimetric pul-
monary nodules. One patient was from group 1-E (lymphoma
patients) and the other patient was from group II (secondary
chest tumors). Both showed on CT, in addition to the main
bulk of the disease, scattered minute parenchymatous lung
nodules, measuring 7–8 mm in size. The main bulk showed
metabolic activity on PET/CT imaging, while the subcentimet-
ric nodules were beyond PET resolution. On short term follow
up studies these nodules remained unchanged and hence con-
sidered indeterminate pulmonary nodules (Table 6).
4. Discussion
The current study is an antegrade evaluation of different cate-
gories of 29 oncology patients suffering from chest tumors, fol-
lowed up over a period of 2 years. All patients were known to
have chest tumors either primary or secondary and were
referred for whole body PET/CT scans. In our study 21Frequency Percent (%)
n pneumonitis 1 3.44
determination line of treatment 1 3.44
4 13.79
21 72.41
2 6.89
29 100.0
/CT.
Frequency Percent (%)
8 27.58
1 3.44
4 13.79
7 24.13
1 3.44
1 3.44
7 24.13
29 100.0
Table 5 Percentage of change of management.
Frequency Percent (%)
Still on treatment 20 68.96
Stopped the treatment 9 31.04
Total 29 100.0
Table 6 Percentage of ﬁndings beyond PET resolution.
Beyond PET resolution Frequency Percent (%)
Multiple subcentimetric pulmonary nodules 2 6.89
None 27 93.11
Total 29 100.0
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chemotherapy and/or radiotherapy: Six patients in group 1-A
(lung tumors), 2 patients in group 1-B (pleural tumors), 1
patient in group 1-C (chest wall tumors), 7 patients in group
1-E (lymphoma patients), 5 patients in group II secondary
chest tumors. CT ﬁndings alone were not conclusive for assess-
ment of treatment response and patients were referred for
PET/CT scan and revealed the following: 7 patients showed
disease progression, 6 cases of disease regression, stationary
course in 4 cases, complete remission for 2 patients, while 1
condition revealed stationary course followed by progressive
course and 1 showed a regressive course followed by progres-
sive course. Accordingly, at the end of the study, 2 patients
were cured and stopped treatment, while 19 patients needed
continuation of treatment. Integrated PET/CT was not only
effective in monitoring the response of the primary tumor
bulk, but was also effective in monitoring the lymph node
affection as well as monitoring distant metastases after chemo-
therapy and/or radiotherapy (case 1 Fig. 1 and case 2 Fig. 2).
We agree with Vikram and Suzanne, (4) that integrated PET/
CT is a good tool for monitoring the response to chemother-
apy and/or radiotherapy. Cronin et al., (5) mentioned that
the residual lymph node mass in the lymphoma cases, repre-
sented a diagnostic challenge, because using CT alone, it was
difﬁcult to differentiate post-treatment ﬁbrosis from residual
viable malignant changes or evaluate therapeutic response by
monitoring changes in size of lymph nodes. In this context,
using integrated PET/CT was useful in the assessment of ther-
apeutic response, discriminating benign ﬁbrosis (low-grade or
absent 18F-FDG uptake) from residual active lymphoma (ele-
vated 18F-FDG uptake), comparing SUV on sequential stud-
ies throughout treatment, a ﬁnding which is consistent with
Cronin et al., (5).
Four patients (13.79%) were referred for differentiation
between tumor residue and postoperative changes. Two of
those were from group 1-B (pleural tumors), known to have
malignant pleural mesothelioma, who had undergone surgical
excision. The CT ﬁndings were not conclusive for assessment
of the tumor residue or the associated mediastinal lymphade-
nopathy, nature of pleural effusion and evaluation of extratho-
racic metastasis. PET/CT study revealed focal metabolically
active FDG avid soft tissue thickening at the mediastinalpleura in both patients. Additional ﬁndings in one patient were
in the form of multiple metabolically active FDG avid nodal
(mediastinal and supraclavicular), hepatic and muscular
deposits (case 3, Fig. 3). This particular case needed further
management. On follow up PET/CT studies 1 patient showed
disease progression and the other patient showed disease
regression. These ﬁndings are in agreement with Gosselin
et al., (6), who considered the differentiation of tumor residual
from pleural ﬁbrosis using integrated PET/CT, the main issue
in mesothelioma patients, which is indistinguishable on classi-
cal anatomical CT imaging. The other two patients were
known to have thymoma, type B2 (group 1-D mediastinal
tumors), who underwent surgical excision and CT ﬁndings
were not conclusive for differentiation between tumor residue
and postoperative changes. They were referred for PET/CT
scan, which revealed metabolically active FDG residual tumor
mass and needed further management (case 5 Fig. 5). Further
follow up PET/CT studies showed complete remission and
both were considered cured. According to Hutchings and Bar-
rington (7), the viability of the residual tissue cannot be
assessed by CT alone. In such cases, 18F-FDG-PET comple-
ments CT by determining whether treated tissue represents
active disease or inactive ﬁbrosis/scar. Two patients (6.89%)
were referred for integrated PET/CT assessment before
BMT, 1 patient (3.44%) was referred for differentiation
between residual tumor versus irradiation pneumonitis, the
other patient was referred for assessment before determination
of the treatment line. CT ﬁndings were not conclusive for
delineation of the metabolic activity of the disease in prepara-
tion for BMT. PET/CT results were positive for both patients
and BMT had to be postponed, which is in agreement with
Spaepen et al. (8), who stated that FDG-PET performed after
salvage chemotherapy and before a combination of high-dose
chemotherapy and stem cell transplantation can help predict
patient outcome. Accordingly, patients with negative pre-
transplantation FDG-PET ﬁndings are unlikely to experience
relapse, while abnormal uptake on pre-transplantation
FDG-PET is associated with tumor progression after
transplantation.
In this study one patient with peripheral bronchogenic car-
cinoma underwent radiotherapy to the lung. CT could not dif-
ferentiate between residual tumor and irradiation pneumonitis.
PET/CT was able to differentiate between these changes and
showed low FDG uptake and consequently was diagnosed as
irradiation pneumonitis. We agree with Larici et al., (9) that
integrated PET/CT appears to provide higher accuracy than
that available with CT alone for distinguishing residual or
recurrent tumor from lung changes after irradiation in patients
with lung cancer. This study included one patient, from the
lymphoma group, who was referred for initial evaluation of
the metabolic activity of the disease before determination of
the treatment line, as CT ﬁndings were not conclusive before
starting treatment. PET/CT was positive and showed metabol-
ically active FDG avid nodal lymphomatous inﬁltrates above
and below the diaphragm. Follow up PET/CT studies revealed
complete remission, followed by progression, then after a neg-
ative study, he was considered cured and stopped treatment.
We agree with Kuehl, (10) that 18F-FDG PET/CT appears
to be signiﬁcantly more accurate in pre-therapeutic staging.
The PET/CT staging protocol should include the chest and
abdomen for local staging and identiﬁcation of distant metas-
tasis. In addition, the neck should be included in the ﬁeld of
Fig. 1 Axial PET/CT (a–c) the initial study images show: multiple metabolically active FDG avid wide spread lesions (a) at the RT
kidney (arrow), (b, c) left lower lung lobe, enlarged bilateral hilar LNs and extensive bilateral pulmonary metabolically active FDG avid
linear and nodular deposits are seen extending from the enlarged hilar LNs (lymphangitis carcinomatosa) (arrows) 2- (d–f) 3 months
follow up study showing rather stationary course.
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Inclusion of the brain to stage potential cerebral metastases
may be of beneﬁt. We advise a whole-body PET/CT protocol
to be included for initial tumor staging. Two patients, one
patient from group 1-E (lymphoma patients) and the other
patient with metastatic cancer breast from group II (secondary
chest tumors) showed on CT, in addition to the main bulk ofdisease, scattered minute parenchymatous lung nodules, 7–
8 mm in size. The main bulk showed metabolic activity on
PET/CT images, while the subcentimetric nodules were
beyond PET resolution (case 4, Fig. 4). On short term follow
up studies these nodules remained unchanged and hence con-
sidered to be indeterminate pulmonary nodules. So, we agree
with the study of Acker and Burrell (11), who stated that
Fig. 2 Axial PET/CT (a–d) the initial study images show: (a) signiﬁcant collapse of the left upper lung lobe with ipsilateral mediastinal
shift with bilateral apical pulmonary cystic changes (likely post irradiation changes) (arrows) (b) metabolically active FDG avid mass
lesion is seen at the left lower lung lobe (arrows), (c) multiple metabolically active FDG avid hepatic deposits (arrows), (d) metabolically
active FDG avid mass lesion is seen at left suprarenal gland (arrow) 2- (e–g) 9 months follow up images show regressive course.
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Fig. 3 Axial PET/CT (a–f) images show: (a, b) focal metabolically active FDG avid soft tissue thickening is seen at the site of
mediastinal pleura, (c) multiple metabolically active FDG left axillary and mediastinal nodal deposits the largest is seen at the subcarinal
LN image (d) (arrows), (e) metabolically active focal hepatic deposits at hepatic right lobe (arrows), (f) focal FDG uptake is seen over the
left trapezius muscle (arrow).
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FDG-PET in which case non invasive imaging, such as serial
CT examinations, should be performed. Maldonado et al.
(12) stated that subcentimetric nodules, apparently fall below
the lower limit for detection by PET and are therefore difﬁcult
to characterize metabolically. A repeat scan should be per-
formed after 3 months. In such cases the volume and metabolicactivity of the nodule should be assessed, and if any increase is
found in either of these parameters, the nodule should be trea-
ted as malignant. There is a debate over how the CT portion in
integrated PET/CT examination should be performed.
Rodriguez-Vigil et al., (13) showed a good correlation between
unenhanced low-dose PET/CT and contrast-enhanced full-
dose PET/CT for lymph node and extra-nodal disease in
686 H. Nabil et al.lymphomas, suggesting that unenhanced low-dose PET/CT
might be sufﬁcient. We found that the use of full dose contrast
enhanced CT for image fusion had an additional value in the
assessment of hilar lymph node involvement, as the intrave-
nous contrast helps in differentiation between the hilar lymph
nodes and the hilar vascular structures. It also allows proper
assessment of mediastinal invasion. The detection of meta-
static hepatic focal lesions is sometimes difﬁcult by PET alone,
as the normal hepatic uptake is patchy and rather heteroge-
neous, so correlating areas of relatively increased 18F-FDG
uptake on PET images to focal lesions on CT images is effec-
tive in conﬁrming the diagnosis. The CT can be considered a
baseline examination, if IV contrast is given for the CT compo-Fig. 4 (a–c) Axial PET/CT and (d) coronal PET/CT images showed
multiple RT lung lobe subcentimetric pulmonary nodules with no cornent of the integrated study, in cases follow up by CT alone is
to be used for further monitoring. The cost of repeated PET/
CT examinations may not be affordable for all patients, which
means that PET/CT with only un-enhanced CT cannot be used
for further CT follow-up. Pfannenberg et al., (14) studied the
additional value of contrast-enhanced multiphase CT in com-
parison with low-dose unenhanced CT in combined PET–
PET/CT protocols for patients with different malignant
tumors in a retrospective study and concluded that diagnostic
multiphase CT as part of the combined PET/CT protocol has
the potential to provide considerable additional value in spe-
ciﬁc clinical conditions, with resultant change of management
in a substantial proportion of patients.MA FDG avid multiple nodal lesions above the diaphragm, (e)
responding FDG uptake (beyond PET/CT resolution).
Fig. 5 (a–b) Axial PET/CT images show (a) metabolically active FDG avid residual superior mediastinal mass lesion (image b) (arrow)
associated with MA FDG avid RT paratracheal LN (image a) (arrow).
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Integrated PET/CT imaging, which combines both functional
and morphologic imaging in a single examination, has shown
how the initial staging and subsequent follow-up of patients
with chest tumors can supersede the traditional methods of
evaluation in terms of diagnostic accuracy and has an impact
on the management. Limitations we encountered were subcen-
timetric pulmonary nodules, below 7 mm (beyond PET resolu-
tion) which can be overcome by short term follow up.
5.1. Cases
Case 1:Male patient, 49 years old, known to have lung cancer.
Received chemotherapy PET/CT scan was requested for
assessment of treatment response. PET/CT scan: revealed mul-
tiple metabolically active FDG avid wide spread lesions at the
RT kidney, lungs (with lymphangitis carcinomatosa) as well as
multiple abdominal and mediastinal LNs.
3 months follow up study: rather stationary course.
Case 2: Male patient, 57 years old, known to have left lung
adenocarcinoma. Received chemotherapy and radiotherapy.
The patient was referred for assessment of the treatment
response PET/CT scan: revealed metabolically active FDG
avid residual primary lung tumor with hepatic and left supra-
renal deposits. 9 month follow up study: Regressive course of
the MA FDG avid residual left lower lung lobe as well as
the distant metastasis.
Case 3: Male patient, 42 years old, known to have left
mesothelioma. The patient received chemotherapy and radio-
therapy after surgical excision and was referred for assessment
of treatment response. PET/CT scan: metabolic active FDG
avid local tumoral recurrence at the mediastinal pleura with
nodal, hepatic and muscular deposits.
Case 4: A female patient, 29 years old, known case of HD
received chemotherapy was referred for assessment of treat-
ment response PET/CT scan: MA FDG avid multiple nodal
lesions above the diaphragm.
Note: CT Findings: Multiple RT lung lobe subcentimetric
pulmonary nodules with no corresponding FDG uptake
(beyond PET/CT resolution).Case 5: Male patient, 34 years old, known to have thy-
moma underwent surgical excision followed by chemotherapy
and was referred for assessment of the residual tumor PET/CT
scan: MA FDG avid residual superior mediastinal mass lesion
associated with MA FDG avid RT paratracheal LN.
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